(2022) conducted a study involving forty-four patients with relapsed/refractory (R/R) DLBCL to assess the safety and efficacy of combining PD-1 inhibitors with anti-CD19 CAR-T cell therapy, followed by PD-1 inhibitor maintenance therapy in DLBCL patients with high tumor burden (138). Here, CD19 is linked to neoplasm.